PPARG and neoplasm: These context-specific effects are also supported by pharmacologic inhibition of AR via bicalutamide, which enhances invasiveness in PCa cells through the circRNA-ARC1/miR-125b-2-3p axis but suppresses BCa invasion through the miR-4736/PPARγ/MMP-9 axis, suggesting the importance of tailoring anti-AR therapies on the basis of tumor type [74].